Marshall Wace, LLP Next Cure, Inc. Transaction History

Marshall Wace, LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$4.76 - $6.24 $66,597 - $87,303	-13,991 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$5.7 - $9.1 $507,670 - $810,491	-89,065 Reduced 86.42%	13,991 $84,000
Q3 2021 Nov 15, 2021	SELL	$6.74 - $8.02 $61,205 - $72,829	-9,081 Reduced 8.1%	103,056 $695,000
Q2 2021 Aug 13, 2021	BUY	$7.6 - $10.28 $475,600 - $643,312	62,579 Added 126.27%	112,137 $900,000
Q1 2021 May 17, 2021	SELL	$9.81 - $13.88 $50,707 - $71,745	-5,169 Reduced 9.45%	49,558 $496,000
Q4 2020 Feb 16, 2021	SELL	$9.47 - $12.43 $469,522 - $616,279	-49,580 Reduced 47.53%	54,727 $596,000
Q3 2020 Nov 16, 2020	BUY	$8.15 - $21.17 $606,384 - $1.58 Million	74,403 Added 248.81%	104,307 $918,000
Q2 2020 Aug 13, 2020	BUY	$21.19 - $40.2 $482,559 - $915,474	22,773 Added 319.35%	29,904 $641,000
Q1 2020 May 15, 2020	BUY	$32.32 - $58.37 $230,473 - $416,236	7,131 New	7,131 $264,000

15.9M

Ticker NXTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,748,800
Market Cap $36.4M
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.